Controlled randomised crossover trial of the eVects of physiotherapy on mobility in chronic multiple sclerosis

Objectives—To determine whether physiotherapy can improve mobility in chronic multiple sclerosis and whether there is a diVerence between treatment at home and as a hospital outpatient? Methods—A randomised controlled crossover trial was undertaken in patients with chronic multiple sclerosis who had diYculty walking and were referred from neurology clinics: allocation was to one of six permutations of three 8 week treatment periods separated by 8 week intervals: treatments consisted of physiotherapy at home, as an outpatient, or “no therapy”. The main outcome measures were based on independent assessments at home and included mobility related disability (primary outcome: the Rivermead mobility index), gait impairments, arm function, mood, and subjective patient and carer ratings. Therapy was assessed by recording delivery, achievement of set targets, patient and carer preference, and cost. Results—On the Rivermead mobility index (scale 0–15) (primary outcome) there was a highly significant (p<0.001) treatment eVect of 1.4–1.5 units favouring hospital or home based therapy over no therapy: this was supported by other measures of mobility, gait, balance, and the assessor’s global “mobility change” score: there was no major diVerence between home and hospital. Carers preferred home treatment but neither they nor patients discerned greater benefit there. Estimated costs of home physiotherapy were £25/session and those at hospital were £18 (including £7 patient travel costs). Conclusion—A course of physiotherapy is associated with improved mobility, subjective wellbeing, and improved mood in chronic multiple sclerosis compared with no treatment but benefit may only last a few weeks: there is little to choose between home and hospital based therapy but the first is more costly, mainly due to skilled staV travelling time. (J Neurol Neurosurg Psychiatry 2001;70:174–179)